bioTheranostics discovers, develops, and commercializes molecular-based diagnostic, prognostic, and predictive tests that support physicians in the treatment of patients with cancer.
bioT3 provides actionable genomic information for accurate diagnosis and treatment and offers value for a broad group of metastatic cancer patients.
Breast Cancer IndexSM
(BCI) provides full risk assessment, with the unique ability to predict both early and late recurrence, as well as likelihood of benefit from extended endocrine therapy.
1.) Ma, et al. Molecular Classification of Human Cancers Using a 92-Gene Real Time Quantitative Polymerase Chain Reaction Assay. Archives of Pathology and Laboratory Medicine, 130: 465-473, 2006. 2.) Erlander et al. Performance and Clinical Evaluation of the 92-Gene Real-Time PCR Assay for Tumor Classification. J Mol Diag. 2011 Sept; 13(5): 493-502. 3.) Kerr SE et al. Multisite Validation Study To Determine Performance Characteristics of a 92-gene Molecular Cancer Classifier. Clin Cancer Res. 2012 May 30. 4.) Jerevall P, et al. Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial. Br J Cancer. 2011 May 24;104(11):1762-9.